EXICURE, INC. Deferred Federal, State and Local, Tax Expense (Benefit)
EXICURE, INC. (XCUR) reported Deferred Federal, State and Local, Tax Expense (Benefit) of -$10.00 thousand for the 6-month period ending 2017-08-31, per its 10-Q filed 2017-09-12.
Discontinued › Expense Statement › Income Tax
us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit · last filed 2017-09-12
- EXICURE, INC. deferred federal, state and local, tax expense (benefit) for the quarter ending 2017-08-31 was -$16.00K.
- EXICURE, INC. deferred federal, state and local, tax expense (benefit) for the quarter ending 2017-05-31 was $6.00K.
| Period end | Deferred Federal, State and Local, Tax Expense (Benefit) 3 month | Deferred Federal, State and Local, Tax Expense (Benefit) 6 month |
|---|---|---|
| 2017-08-31 | -$16.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-09-12 | -$10.00K 10-Q · filed 2017-09-12 |
| 2017-05-31 | $6.00K 10-Q · filed 2017-07-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |